Rontalizumab, a novel monoclonal antibody , demonstrates significant scope in targeting specific inflammatory pathways. This innovative treatment shows the chance to inhibit interleukin-6 receptor (IL-6R), a https://www.targetmol.com/compound/rontalizumab